Neuropathic pain is the sensation of pain due to abnormal discharges of impaired or injured neural structures in the peripheral &/or central nervous system.
It is characterized by hyperesthesia, hyperalgesia and allodynia.
Common neuropathic pain syndromes are central neuropathic pain, painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, postsurgical neuropathic pain, HIV-related neuropathy, lumbosacral radiculopathy and complex regional pain syndrome.
New drug applications approved by US FDA as of 1 - 15 October 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Capsaicin 8% patch shows potential as a long-term treatment option for non-diabetic patients with peripheral neuropathic pain, with a new study reporting that repeat treatment over 52 weeks is well tolerated, producing sustained reductions in average pain intensity with variable sensory function alteration and minimal chance of complete sensory loss.
Duloxetine demonstrates long-term safety and efficacy in the treatment of Japanese patients with diabetic neuropathic pain, as observed in a 52-week, randomised, open-label extension of a 12-week, double-blind, placebo-controlled study.
New drug applications approved by US FDA as of 1 - 15 Oct 2015 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.
Topical menthol may be a new analgaesic for cancer treatment-associated neuropathic pain caused by chemotherapy-induced peripheral neuropathy or surgical scars, as presented in a proof of concept study.
Liposomal topical capsaicin exhibits safety and good tolerability in patients with post herpetic neuralgia who continued to be symptomatic after first- and second-line treatment, based on a pilot study.
There is an over-representation of women in published reports of celecoxib drug-induced liver injury (DILI), according to a recent study. Latency has been shown to be short (<3 months) in most patients, but some of them may present with DILI after prolonged use of celecoxib.
In males with primary or secondary hypogonadism (HG), adherence to topical testosterone therapy (TTh) appears to improve total testosterone and decrease the risk of conditions associated with HG, a recent study has shown.